SeaStar Medical to Report First Quarter Financial Results on May 13, 2026
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) will report first quarter 2026 financial results after market close on Wednesday, May 13, 2026.
The company will host a webcast and conference call at 4:30 p.m. ET / 2:30 p.m. MT with preregistration required; a replay will be available after 7:30 p.m. ET.
Positive
- None.
Negative
- None.
News Market Reaction – ICU
In the May 6 session, ICU gained 10.18%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.4% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Earnings date notice | Neutral | -3.4% | Announced date and time for Q4 and full-year 2025 earnings call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date scheduling news was followed by a modest negative move of -3.4%.
Over recent months SeaStar Medical has combined regulatory and clinical progress with regular financial updates. The company reported 2025 results on March 25, 2026, showing higher revenue and a narrower net loss, which was followed by a positive share reaction. An earlier earnings date announcement on March 18, 2026 saw a modest decline. The new notice of first-quarter results on May 13, 2026 continues this pattern of scheduled communications to discuss financials and business progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 13, 2026, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Wednesday, May 13, 2026, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here. |
| Register for the call: | Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration. |
A replay of the call will be available after 7:30 p.m. ET and can be accessed here.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
